Evidence map›Paper›PMID 37849789›Full record

ArticleInfection and drug resistance2023

Haffsatou Sawadogo, Issiaka Soulama, Adama Zida, Cheikna Zongo, Patindoilba Marcel Sawadogo, Kiswendsida Thierry Guiguemde, Seni Nikiema, Salimata Emilie Badoum, Salam Sawadogo, Aïcha Tou and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infection and drug resistance, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Haffsatou SawadogoLaboratory of Applied Biochemistry and Immunology (LABIA), Joseph KI - ZERBO University, Ouagadougou, Burkina Faso.
Issiaka SoulamaHealth Science Research Institute (IRSS), Ouagadougou, Burkina Faso.ORCID 0000-0002-0993-0525
Adama ZidaParasitology-Mycology Department, Centre Hospitalier Universitaire Yalgado Ouédraogo (CHU-YO), Ouagadougou, Burkina Faso.
Cheikna ZongoLaboratory of Applied Biochemistry and Immunology (LABIA), Joseph KI - ZERBO University, Ouagadougou, Burkina Faso.ORCID 0000-0003-3109-8509
Patindoilba Marcel SawadogoParasitology-Mycology Department, Centre Hospitalier Universitaire Yalgado Ouédraogo (CHU-YO), Ouagadougou, Burkina Faso.
Kiswendsida Thierry GuiguemdeHealth Sciences Training and Research Unit (UFR/SDS), Joseph KI - ZERBO University, Ouagadougou, Burkina Faso.ORCID 0000-0002-9426-7464
Seni NikiemaMolecular Biology and Genetics Laboratory (LABIOGENE), Joseph KI - ZERBO University, Ouagadougou, Burkina Faso.
Salimata Emilie BadoumLaboratory of Applied Biochemistry and Immunology (LABIA), Joseph KI - ZERBO University, Ouagadougou, Burkina Faso.
Salam SawadogoMolecular Biology and Genetics Laboratory (LABIOGENE), Joseph KI - ZERBO University, Ouagadougou, Burkina Faso.
Aïcha TouNational Malaria Research and Training Center (CNRFP), Ouagadougou, Burkina Faso.
Salif SombiéNational Malaria Research and Training Center (CNRFP), Ouagadougou, Burkina Faso.
Chanolle TchekounouLaboratory of Applied Biochemistry and Immunology (LABIA), Joseph KI - ZERBO University, Ouagadougou, Burkina Faso.
Sindié Samuel SerméLaboratory of Applied Biochemistry and Immunology (LABIA), Joseph KI - ZERBO University, Ouagadougou, Burkina Faso.
Rasmata Ouedraogo-TraoréInternational Institute of Science and Technology (Iistech), Ouagadougou, Burkina Faso.
Tinga Robert GuiguemdéParasitology-Mycology Laboratory, National Institute of Health Sciences (INSP), Nazi Boni University, Bobo-Dioulasso, Burkina Faso.
Aly SavadogoLaboratory of Applied Biochemistry and Immunology (LABIA), Joseph KI - ZERBO University, Ouagadougou, Burkina Faso.
Université Joseph Ki-Zerbo · BFMalariaGEN · BFInternational Institute for Water and Environmental Engineering · BFNazi Boni University · BF

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Intermittent preventive treatment with sulfadoxine-pyrimethamine is widely used for the prevention of malaria in pregnant women in Africa. Known resistance cases of sulfadoxine-pyrimethamine during pregnancy need to be follow up to support IPTp implementation in Burkina Faso. However, data on the development and spread of resistance to this molecule are lacking. This study aimed to investigating the genetic diversity of Patients and Methods: This was a prospective and cross-sectional study conducted between April 2019 and March 2020 in four health districts of Ouagadougou capital city. From the placentas collected after delivery, Results: PCR-positive samples were estimated at 96% for Conclusion: The results showed that

Indexed as

dhfrdhpsmsp1msp2placentaPlasmodium falciparumsulfadoxine-pyrimethamine

Identifiers

PMID37849789
PMCPMC10578158
OpenAlexW4387542306

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.